Figure 5.

AB1-HA, AB12 and Line-1M tumour and dLN lymphocyte expression of ICP receptors.

Flow cytometry was used to assess ICP expression profiles of tumour and draining lymph node resident immune cells harvested from mice bearing small (day 10, ~ 25 mm²) AB1-HA, AB12 or Line-1M tumours. (A) Experimental design. (B) Gating strategy for identification of CD4 (CD3+ CD4+ FoxP3-), Treg (CD4+ CD25+ FoxP3+) and CD8 (CD3+ CD8+) lymphocytes, each of which were further gated in histogram plots depicting MFI expression of CTLA-4, GITR, OX40, PD-1 and TIM-3. (C) Tumour CD3 frequency of total live cells; CD4, Treg and CD8 percentage frequency of CD3 population and frequency of TIL ICP receptor expression for CD4, Treg and CD8 T cells. (D) Tumour dLN CD3 percentage frequency of total live cells, and CD4, Treg and CD8 percentage frequency of CD3 population. Tumour dLN frequency of ICP receptor expression for CD4, Treg and CD8 T cells. CD4 (white), Treg (black) and CD8 (hatched) columns, n = 5–9 mice/group from two independent experiments, data are mean ± SEM; One Way ANOVA *p < 0.05, **p < 0.01 compared to respective AB1-HA population.